Search hospitals > Ontario > TORONTO
Sunnybrook Research Institute
Claim this profileTORONTO, Ontario M4N 3M5
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Melanoma
Conducts research for Prostate Cancer
Conducts research for Solid Tumors
92 reported clinical trials
14 medical researchers
Summary
Sunnybrook Research Institute is a medical facility located in TORONTO, Ontario. This center is recognized for care of Breast Cancer, Cancer, Melanoma, Prostate Cancer, Solid Tumors and other specialties. Sunnybrook Research Institute is involved with conducting 92 clinical trials across 112 conditions. There are 14 research doctors associated with this hospital, such as Sandra Black, MD, Laurence Klotz, MD, Andrew Loblaw, MD, and Nir Lipsman, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Cancer
Global LeaderStage IV
Stage III
BRAF
Top PIs
Sandra Black, MDSunnybrook Health Sciences Centre5 years of reported clinical research
Studies Alzheimer's Disease
Studies Mild Cognitive Impairment
10 reported clinical trials
21 drugs studied
Laurence Klotz, MDSunnybrook Health Sciences Centre5 years of reported clinical research
Studies Prostate Cancer
Studies Recurrence
8 reported clinical trials
17 drugs studied
Andrew Loblaw, MDSunnybrook Health Sciences Centre6 years of reported clinical research
Studies Prostate Cancer
Studies Recurrence
7 reported clinical trials
9 drugs studied
Nir Lipsman, MDSunnybrook Research Institute4 years of reported clinical research
Studies Brain Tumor
Studies Glioblastoma
7 reported clinical trials
10 drugs studied
Clinical Trials running at Sunnybrook Research Institute
Breast Cancer
Brain Tumor
Prostate Cancer
Ovarian Cancer
Melanoma
Solid Tumors
Non-Small Cell Lung Cancer
Lymphoma
Blood Cancers
Endometrial Cancer
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Recruiting4 awards Phase 3
ARV-471
for Breast Cancer
This trial tests a new oral medicine, ARV-471, against an existing injectable treatment, fulvestrant, in people with advanced breast cancer that has spread. Both medicines aim to slow cancer growth by targeting estrogen receptors. ARV-471 is developed as an oral alternative to fulvestrant.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Sunnybrook Research Institute?
Sunnybrook Research Institute is a medical facility located in TORONTO, Ontario. This center is recognized for care of Breast Cancer, Cancer, Melanoma, Prostate Cancer, Solid Tumors and other specialties. Sunnybrook Research Institute is involved with conducting 92 clinical trials across 112 conditions. There are 14 research doctors associated with this hospital, such as Sandra Black, MD, Laurence Klotz, MD, Andrew Loblaw, MD, and Nir Lipsman, MD.